While the impact of Lp(a) reduction on stroke prevention remains uncertain, the use of a PCSK9 inhibitor in this case was based on its dual lipid-lowering properties and its potential role in secondary prevention and risk modification. The gene discussed is PCSK9; the disease is Stroke.